Drug Profile


Alternative Names: Amoxicillin/pantoprazole/rifabutin; Amoxicillin/rifabutin/omeprazole; Heliconda; Omeprazole/amoxicillin/rifabutin; RHB-105; Rifabutin/amoxicillin/omeprazole; TALICIA

Latest Information Update: 28 Jun 2017

Price : $50

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antibacterials; Antituberculars; Antiulcers; Benzimidazoles; Gastric antisecretories; Penicillins; Rifamycins; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 50S ribosomal subunit inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Helicobacter infections

Most Recent Events

  • 15 Jun 2017 RedHill Biopharma initiates enrolment in the confirmatory phase III ERADICATE Hp2 trial for Helicobacter infections in the US (NCT03198507)
  • 12 May 2017 Amoxicillin/omeprazole/rifabutin is still at phase III development stage for Helicobacter infections (Treatment-naive) in USA (PO) (RedHill Biopharma pipeline, May 2017)
  • 16 Nov 2016 RedHill Biopharma concludes a Type B meeting with the US FDA for amoxicillin/omeprazole/rifabutin in Helicobacter pylori infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top